IP Library › Granted Patent US 7,309,789
Granted Patent B2
US 7,309,789 · App. 11/438,725 · Granted Dec 18, 2007

4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof

Assignee: AMR Technology, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,309,789
App. No.
11/438,725
Granted
Dec 18, 2007
Kind
B2
Abstract

Compounds are provided that, by way of their selective neurotransmitter binding useful for the treatment of various neurological and psychological disorders, e.g., ADHD. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

Claims (51)

1. A compound of Formula (50):

or a pharmaceutically acceptable salt form thereof, wherein R 3 is H, R 4 is H, R 5 is H and R 6 is H.

2. A compound of Formula (60):

or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

a compound of Formula (60) wherein R 3 is H, R 4 is H, R 5 is H and R 6 is H and R 13 is H;

a compound of Formula (60) wherein R 3 is H, R 4 is H, R 5 is H, R 6 is H and R 13 is Me;

a compound of Formula (60) wherein R 3 is H, R 4 is H, R 5 is H, R 6 is H and R 13 is Et;

a compound of Formula (60) wherein R 3 is H, R 4 is H, R 5 is F, R 6 is F and R 13 is H;

a compound of Formula (60) wherein R 3 is H, R 4 is H, R 5 is F, R 6 is F and R 13 is Me;

a compound of Formula (60) wherein R 3 is H, R 4 is F, R 5 is H, R 6 is F and R 13 is H;

a compound of Formula (60) wherein R 3 is H, R 4 is F, R 5 is H, R 6 is F and R 13 is Me;

a compound of Formula (60) wherein R 3 is H, R 4 is Cl, R 5 is H, R 6 is H and R 13 is H;

a compound of Formula (60) wherein R 3 is H, R 4 is Cl, R 5 is H, R 6 is H and R 13 is Me;

a compound of Formula (60) wherein R 3 is H, R 4 is F, R 5 is H, R 6 is H and R 13 is H;

a compound of Formula (60) wherein R 3 is H, R 4 is H, R 5 is F, R 6 is H and R 13 is H;

a compound of Formula (60) wherein R 3 is H, R 4 is F, R 5 is Cl, R 6 is H and R 13 is H;

a compound of Formula (60) wherein R 3 is H, R 4 is F, R 5 is Cl, R 6 is H and R 13 is Me;

a compound of Formula (60) wherein R 3 is H, R 4 is Cl, R 5 is F, R 6 is H and R 13 is H; and

a compound of Formula (60) wherein R 3 is H, R 4 is Cl, R 5 is F, R 6 is H and R 13 is Me.

3. A compound of Formula (70):

or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

a compound of Formula (70) wherein R 3 is H, R 4 is H, R 5 is H, R 6 is H and R 13 is H;

a compound of Formula (70) wherein R 3 is H, R 4 is H, R 5 is H, R 6 is H and R 13 is Me;

a compound of Formula (70) wherein R 3 is H, R 4 is H, R 5 is H, R 6 is H and R 13 is Et;

a compound of Formula (70) wherein R 3 is H, R 4 is H, R 5 is H, R 6 is H and R 13 is Bn;

a compound of Formula (70) wherein R 3 is H, R 4 is H, R 5 is F, R 6 is F and R 13 is H;

a compound of Formula (70) wherein R 3 is H, R 4 is H, R 5 is F, R 6 is F and R 13 is Me;

a compound of Formula (70) wherein R 3 is H, R 4 is F, R 5 is H, R 6 is F and R 13 is Me;

a compound of Formula (70) wherein R 3 is H, R 4 is Cl, R 5 is H, R 6 is H and R 13 is H;

a compound of Formula (70) wherein R 3 is H, R 4 is Cl, R 5 is H, R 6 is H and R 13 is Me;

a compound of Formula (70) wherein R 3 is H, R 4 is F, R 5 is H, R 6 is H and R 13 is H;

a compound of Formula (70) wherein R 3 is H, R 4 is F, R 5 is H, R 6 is H and R 13 is Me;

a compound of Formula (70) wherein R 3 is H, R 4 is H, R 5 is F, R 6 is H and R 13 is H;

a compound of Formula (70) wherein R 3 is H, R 4 is F, R 5 is Cl, R 6 is H and R 13 is H;

a compound of Formula (70) wherein R 3 is H, R 4 is F, R 5 is Cl, R 6 is H and R 13 is Me;

a compound of Formula (70) wherein R 3 is H, R 4 is Cl, R 5 is F, R 6 is H and R 13 is H; and

a compound of Formula (70) wherein R 3 is H, R 4 is Cl, R 5 is F, R 6 is H and R 13 is Me.

4. A compound of Formula (100):

or a pharmaceutically acceptable salt form thereof, wherein R 4 is H, R 5 is H, R 6 is H and R 13 is H.

5. A compound of Formula (130):

or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

a compound of Formula (130) wherein R 4 is H, R 5 is H and is R 6 is H; and

a compound of Formula (130) wherein R 4 is H, R 5 is Bn and R 6 is H.

6. A compound of Formula (160):

or a pharmaceutically acceptable salt form thereof, wherein R 4 is H, R 5 is H and R 6 is H.

7. A compound of Formula (190):

or a pharmaceutically acceptable salt form thereof, wherein R 4 is H, R 5 is H and R 6 is H.

8. A compound of Formula (200):

or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

a compound of Formula (200) wherein R 4 is H, R 5 is H, R 6 is H and R 13 is H; and

a compound of Formula (200) wherein R 4 is H, R 5 is H, R 6 is H and R 13 is Me.

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 7541537 PREVIOUSLY RECORDED AT REEL: 034045 FRAME: 0951. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 14, 2018
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 046796/0352 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2017
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC; AMRI SSCI, LLC; EUTICALS INC.
Reel/Frame 043742/0085 →
SECURITY INTEREST Recorded Oct 24, 2014
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 034045/0951 →
RELEASE OF SECURITY INTEREST Recorded Jul 9, 2014
From: WELLS FARGO
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 033283/0357 →
SECURITY AGREEMENT Recorded Apr 20, 2012
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI RENESSELAER, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 028078/0227 →
TERMINATION Recorded Apr 19, 2012
From: BANK OF AMERICA, N.A.
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.; AMRI RENESSELAER, INC.
Reel/Frame 028072/0335 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 6, 2011
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI RENSSELAER, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026397/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2008
From: AMR TECHNOLOGY, INC.
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 021998/0550 →
Continuity (3)
Division 0990284500 · Jul 11, 2001
Provisional Application 6021741200 · Jul 11, 2000
Related Publication 20060217409A1 · Sep 28, 2006